



SCOTTSDALE  
HEALTHCARE<sup>SM</sup>

## **Shea Cancer Program**

**Annual Report – 2014**

## Table of Contents

Cancer Program Activities	3
Physician Cancer Committee Members	4
Non-Physician Cancer Committee Members	4
Cancer Conferences	5
Top Ten Analytic Cancer Incidence by Gender - Male	5
Top Ten Analytic Cancer Incidence by Gender - Female	6
Analytic Incidence by Age Group and Gender	5
Standard of Care Quality Measures of the Commission on Cancer	6
System-wide 2013 Primary Site Table	7
Shea 2013 Primary Site Table	9
Osborn 2013 Primary Site Table	11
Thompson Peak 2013 Primary Site Table	12

**Community Outreach at Scottsdale Healthcare is very active. In 2014, cancer programs alone numbered 537 with 15,496 participants plus exposure to an additional 14,523 people at four large events (Parada Del Sol, Leukemia/Lymphoma Walk, Lung Walk, and Komen) for a total of 30,019 people.**

**Community Outreach Support Group Meetings Included:**

- BRCATEERS (BRCA Positive Support Group)
- Women of Scottsdale
- West Valley Women
- Central Phoenix Women
- Cancer Support and Education Forum
- East Valley Women
- Network of Strength Breast Cancer Support Group
- Pancreatic Support Group
- Diabetes Support Group
- Facing Forward Women's Support Group
- AZ Myeloma Network Caregiver Education Support Program

**Community Outreach Events:**

- Parada Del Sol Parade
- Parada Del Sol Rodeo
- Susan G. Komen Walk
- American Cancer Society Breakfast
- Pancreatic Community Event
- Social Work Luncheon
- Lymphoma Walk Breakfast
- Annual stepNout Run Walk

- Phoenix Symphony Trio – Healing Power of Music
- Cervical and Gynecological Cancer Event
- Making Strides Against Cancer
- Celebration of Life Leukemia / Lymphoma Walk
- LPGA Charity Pro-Am
- Interfaith Breakfast
- My Hope Bag – Breast Health Event
- Gift of Life Lodging Program
- Lung Force Walk
- Light the Bridge from Care to Cure Event – Human Cancer Ribbon
- Bone Marrow Drive Event
- Annual Celebration of Lights
- Tina's Treasures Sweet Spring Annual Event
- Nutrition/Colon Event
- Celebration of Life Annual Celebration
- Ladies Event for Women of Scottsdale, Central Phoenix Women, and East Valley Women
- Annual National Cancer Survivorship Day Celebration

**Community Outreach Cancer Screenings Included:**

- LPGA Golf Tournament Risk and Prevention Skin Screenings
- Skin Screening – Partnered with Center for Dermatology

- Breast Health Promotional Program and UV Facial Screening
- Annual Skin Cancer Screening and Ocular Melanoma Screening
- Annual Prostate Screening

- Ask Expert Sugar Talk
- Sunflower Health Flower

**Community Outreach Educational Programs Included:**

- MPBC Golf Classic – Anthem
- Decoding Annie Parker – Genetic Panel
- Desert Cancer Foundation Annual Learning Living with Cancer
- Be the Match Bone Marrow Donor Education
- Lymphedema Education Program
- Ladies’ Night Education Resources
- Smoking Cessation Classes
- Cancer Risk and Prevention
- The Transplant Experience
- An Insider’s Look at Stem Cell Transplant

**Community Outreach Complementary Therapy Programs Included:**

- Yoga
- Tai Chi
- Qi Gong
- Healing Art
- Meditation
- Drumming
- Holistic Assessment
- Reiki
- Relaxation Sessions

<b>Physician Committee Members</b>	<b>2014</b>
Jeffrey Isaacs	Medical Oncology
Patrick Donovan	Medical Oncology
Jeffrey Van Lier Ribbink	General Surgery
Farley Yang	Radiation Oncology
James Newell	Pathology
Ron Korn	Radiology
Ramesh Ramanathan	Medical Oncology / Research

**Community Outreach Nutrition Programs Included:**

- Eating For Life – Eat Real
- National Lymphoma Research Conference
- Nutrition Talk for Wellness Community
- Scottsdale Clinical Research Institute In-service for Staff
- Colorectal Survivorship Symposium
- Get Fit While You Sit
- Brighton Power of Pink
- Colon Cancer Alliance Group

<b>Non-Physician Members</b>	<b>2014</b>
Matt Schneider	Vice President
Selma Kendrick	Director- Oncology Service Line
Colleen McKeague	Medical Staff
Donald Day	Oncology Manager
Carol Guarnieri	Oncology Nurse Specialist
Shanna Levy	Genetic Counseling
Gerrie Jakobs	Oncology Social Worker

Nancy McCutcheon	Community Outreach Manager
Faith Henson	Mgr Surgical Oncology
Melanie O'Hara	Care Coordinator
Marlene Miller	Care Coordinator
Terri Taylor	Nutrition Services
Terry Thomas	Cancer Registry
Allison Young	Oncology Nurse Clinician

**2014 Shea Cancer Conferences**

There were 71 tumor boards held at Shea in 2014 (42 general, 22 breast, 4 endocrine and 3 sarcoma). There were 292 cases presented (178 general, 92 breast, 10 endocrine and 12 sarcoma). Of them 287 (98.3%) were prospective presentations.

Physician attendance at Shea tumor boards averaged 12.2; 12.3 at general, 13.2 at breast, 9.5 at endocrine and 7.7 at sarcoma.

Non-physician attendance at Shea tumor boards averaged 9.0; 9.9 at general, 9.0 at breast, 3.0 at endocrine and 4.7 at sarcoma.

There were an additional 41 general tumor boards held at Osborn in 2014 with an average physician attendance of 11.0 per meeting and an average attendance of 3.1 non-physicians per meeting.

**Ten Most Common Analytic Cancers Per Gender (2013 data)**

Male Top Ten Sites	Incidence	Percentage Of Total Male Cases (n=841)
Prostate	269	32%
Bladder	104	12%
Leukemia	79	9%
Lung	56	7%
Melanoma	47	6%

<b>Kidney</b>	47	6%
<b>Colon</b>	37	4%
<b>Thyroid</b>	33	4%
<b>Lymphoma</b>	31	4%
<b>Pancreas</b>	22	3%
<b>Female Top Ten Sites</b>	<b>Incidence</b>	<b>Percentage Of Total Female Cases (n=912)</b>
<b>Breast</b>	359	39%
<b>Thyroid</b>	131	14%
<b>Lung</b>	64	7%
<b>Leukemia</b>	45	5%
<b>Melanoma</b>	35	4%
<b>Bladder</b>	35	4%
<b>Ureter</b>	31	3%
<b>Colon</b>	29	3%
<b>Lymphoma</b>	27	3%
<b>Kidney</b>	23	3%

Note: Cervical carcinoma in situ, squamous or basal cell carcinomas of skin and intraepithelial neoplasias were excluded.

Among men, prostate cancer was the most prevalent. Prostate cancer accounted for 31.9 of every 100 cancers accessioned at Shea among men.

Among women, breast cancer was the most prevalent. Breast cancer accounted for 39.4 of every 100 cancers accessioned at Shea among women.

**Analytic Cases  
Age by Gender (2013 data)**

Age	Male	Female	Total
1-9	0	1	1
10-19	6	2	8
20-29	11	16	27
30-39	20	52	72
40-49	45	125	170
50-59	145	194	339
60-69	280	238	518
70-79	247	189	436
80-89	72	75	147
90-99	15	20	35
≥ 100	0	0	0
Total	841	912	1753

Patients in their sixties accounted for 29.5% of all accessions in 2013. Patients in their fifties and in their seventies accounted for 19.3% and 24.9%, respectively. Collectively, patients of age 50 – 79 accounted for 73.8% of all 2013 cases.

**SCOTTSDALE HEALTHCARE SHEA  
Cancer Program Practice Profile Reports Summary for Breast, Colon, Gastric,  
Non-Small Cell Lung Cancer and Rectal Cancers**

Performance rates from the Commission on Cancer National Cancer Data Base for 2011 diagnoses comparison among SHC Shea, SHC Shea’s upper limit of the 95% Confidence Interval, all Arizona accredited programs, and all CoC accredited programs.

**Per Standard 4.5, the facility’s upper limit of the 95% Confidence Interval for each performance measure must equal or exceed the corresponding performance rate specified by the CoC.**

**Breast Cancer Measures**

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
*Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer. <b>(Unspecified %)</b>	51.6%	57.8%	55.8%	64.0%
Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer <b>(80%)</b>	80.3%	<b>85.4%</b>	77.9%	83.2%
Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with ≥ 4 positive regional lymph nodes <b>(90%)</b>	83.3%	100%	72.5%	79.4%
Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer <b>(90%)</b>	87.0%	<b>94.9%</b>	80.4%	92.7%
Combination chemotherapy is considered or administered within 4 months of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer <b>(90%)</b>	100%	<b>100%</b>	89.8%	93.1%

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer <b>(90%)</b>	91.7%	96.2%	76.3%	91.8%
---	-------	-------	-------	-------

**Colon Cancer Measures**

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer <b>(90%)</b>	100%	100%	78.5%	91.7%
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer <b>(85%)</b>	97.6%	100%	86.0%	87.8%

**Rectal Cancer Measure**

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
*Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer <b>(Unspecified %)</b>	100%	100%	70.8%	92.7%

**The 95% Confidence Interval (C.I.) is a statistical tool for interpreting comparison data. In simplest terms, it means that there is a 95% chance that the true average value is contained within the specified range. The Commission on Cancer specifies that the upper limit of the 95% C.I. of a facility's measure should meet or exceed either the published standard's expected percentage or the actual percentage of all CoC accredited programs, collectively.**

**PRIMARY SITE TABULATION FOR 2013 SCOTTSDALE HEALTHCARE SYSTEM**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
<b>ALL SITES</b>	2648	1223	1425	230	849	465	291	360	187	266
<b>ORAL CAVITY</b>	53	37	16	0	14	7	5	22	5	0
LIP	1	1	0	0	1	0	0	0	0	0
TONGUE	20	13	7	0	4	2	4	7	3	0
OROPHARYNX	2	1	1	0	0	0	0	2	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	30	22	8	0	9	5	1	13	2	0
<b>DIGESTIVE SYSTEM</b>	345	192	153	5	75	93	61	90	17	4
ESOPHAGUS	17	12	5	0	5	4	1	5	2	0

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

STOMACH	24	9	15	1	7	6	3	6	1	0
COLON	122	70	52	2	27	37	28	25	2	1
RECTUM	66	38	28	1	18	15	14	10	8	0
ANUS/ANAL CANAL	8	2	6	0	3	2	1	1	1	0
LIVER	16	10	6	0	8	0	1	7	0	0
PANCREAS	63	36	27	0	5	25	5	27	1	0
OTHER	29	15	14	1	2	4	8	9	2	3
<b>RESPIRATORY SYSTEM</b>	261	124	137	1	74	29	47	104	5	1
NASAL/SINUS	2	2	0	0	1	1	0	0	0	0
LARYNX	10	9	1	1	3	2	1	3	0	0
LUNG/BRONCHUS	246	111	135	0	69	26	46	99	5	1
OTHER	3	2	1	0	1	0	0	2	0	0
<b>BLOOD &amp; BONE MARROW</b>	153	90	63	0	0	0	3	3	0	147
LEUKEMIA	82	46	36	0	0	0	3	3	0	76
MULTIPLE MYELOMA	39	21	18	0	0	0	0	0	0	39
OTHER	32	23	9	0	0	0	0	0	0	32
<b>BONE</b>	10	4	6	0	4	2	0	0	4	0
<b>CONNECT/SOFT TISSUE</b>	44	31	13	0	11	8	15	5	4	1
<b>SKIN</b>	146	79	67	19	66	24	8	7	17	5
MELANOMA	138	76	62	19	63	22	8	7	16	3
OTHER	8	3	5	0	3	2	0	0	1	2
<b>BREAST</b>	457	4	453	95	195	103	30	13	21	0
<b>FEMALE GENITAL</b>	173	0	173	1	76	8	28	20	35	5
CERVIX UTERI	20	0	20	0	9	1	4	1	5	0
CORPUS UTERI	99	0	99	0	59	1	9	8	22	0
OVARY	35	0	35	0	5	2	14	8	6	0
VULVA	13	0	13	1	3	4	1	2	1	1
OTHER	6	0	6	0	0	0	0	1	1	4
<b>MALE GENITAL</b>	309	309	0	0	115	126	35	20	11	2
PROSTATE	299	299	0	0	112	125	34	20	8	0
TESTIS	8	8	0	0	3	1	1	0	2	1
OTHER	2	2	0	0	0	0	0	0	1	1
<b>URINARY SYSTEM</b>	276	204	72	109	76	31	16	21	21	2
BLADDER	166	130	36	103	18	26	8	9	2	0
KIDNEY/RENAL	96	69	27	1	53	5	8	10	19	0
OTHER	14	5	9	5	5	0	0	2	0	2
<b>BRAIN &amp; CNS</b>	36	16	20	0	0	0	0	0	0	36
BRAIN (BENIGN)	1	1	0	0	0	0	0	0	0	1
BRAIN (MALIGNANT)	16	7	9	0	0	0	0	0	0	16
OTHER	19	8	11	0	0	0	0	0	0	19



Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

<b>ENDOCRINE</b>	193	41	152	0	111	7	17	11	43	4
THYROID	189	40	149	0	111	7	17	11	43	0
OTHER	4	1	3	0	0	0	0	0	0	4
<b>LYMPHATIC SYSTEM</b>	123	61	62	0	31	25	18	42	2	5
HODGKIN'S DISEASE	12	4	8	0	2	6	1	3	0	0
NON-HODGKIN'S	111	57	54	0	29	19	17	39	2	5
<b>UNKNOWN PRIMARY</b>	46	23	23	0	0	0	0	0	0	46
<b>OTHER/ILL-DEFINED</b>	23	8	15	0	1	2	8	2	2	8

Number of cases excluded: 4

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION FOR 2013-SHEA-ANALYTIC**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
<b>ALL SITES</b>	<b>1680</b>	<b>807</b>	<b>873</b>	<b>182</b>	<b>566</b>	<b>320</b>	<b>173</b>	<b>179</b>	<b>118</b>	<b>142</b>
<b>ORAL CAVITY</b>	30	16	14	0	9	4	2	13	2	0
LIP	1	1	0	0	1	0	0	0	0	0
TONGUE	10	4	6	0	2	1	1	5	1	0
OROPHARYNX	1	1	0	0	0	0	0	1	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	18	10	8	0	6	3	1	7	1	0
<b>DIGESTIVE SYSTEM</b>	191	102	89	2	44	51	36	48	7	3
ESOPHAGUS	10	7	3	0	3	2	1	4	0	0
STOMACH	16	6	10	1	4	5	1	4	1	0
COLON	65	37	28	0	18	17	16	12	2	0
RECTUM	33	18	15	1	11	9	6	4	2	0
ANUS/ANAL CANAL	5	2	3	0	2	1	0	1	1	0
LIVER	2	0	2	0	1	0	0	1	0	0
PANCREAS	42	22	20	0	3	15	5	18	1	0
OTHER	18	10	8	0	2	2	7	4	0	3
<b>RESPIRATORY SYSTEM</b>	120	58	62	0	39	13	21	45	2	0
NASAL/SINUS	1	1	0	0	0	1	0	0	0	0
LARYNX	3	2	1	0	1	2	0	0	0	0
LUNG/BRONCHUS	115	54	61	0	38	10	21	44	2	0

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

OTHER	1	1	0	0	0	0	0	1	0	0
<b>BLOOD &amp; BONE MARROW</b>	107	65	42	0	0	0	1	1	0	105
LEUKEMIA	53	31	22	0	0	0	1	1	0	51
MULTIPLE MYELOMA	32	18	14	0	0	0	0	0	0	32
OTHER	22	16	6	0	0	0	0	0	0	22
<b>BONE</b>	8	2	6	0	2	2	0	0	4	0
<b>CONNECT/SOFT TISSUE</b>	27	19	8	0	8	7	6	4	2	0
<b>SKIN</b>	75	44	31	12	39	9	3	2	10	0
MELANOMA	73	43	30	12	38	9	3	2	9	0
OTHER	2	1	1	0	1	0	0	0	1	0
<b>BREAST</b>	344	2	342	77	143	79	22	7	16	0
<b>FEMALE GENITAL</b>	51	0	51	0	20	3	6	7	12	3
CERVIX UTERI	2	0	2	0	0	0	0	0	2	0
CORPUS UTERI	30	0	30	0	18	1	2	2	7	0
OVARY	13	0	13	0	1	2	4	4	2	0
VULVA	1	0	1	0	1	0	0	0	0	0
OTHER	5	0	5	0	0	0	0	1	1	3
<b>MALE GENITAL</b>	261	261	0	0	93	111	31	14	10	2
PROSTATE	253	253	0	0	90	111	30	14	8	0
TESTIS	7	7	0	0	3	0	1	0	2	1
OTHER	1	1	0	0	0	0	0	0	0	1
<b>URINARY SYSTEM</b>	220	158	62	91	57	26	15	10	19	2
BLADDER	138	105	33	89	12	23	7	5	2	0
KIDNEY/RENAL	74	50	24	1	41	3	8	4	17	0
OTHER	8	3	5	1	4	0	0	1	0	2
<b>BRAIN &amp; CNS</b>	4	3	1	0	0	0	0	0	0	4
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	1	0	1	0	0	0	0	0	0	1
OTHER	3	3	0	0	0	0	0	0	0	3
<b>ENDOCRINE</b>	158	33	125	0	96	5	16	6	33	2
THYROID	156	33	123	0	96	5	16	6	33	0
OTHER	2	0	2	0	0	0	0	0	0	2
<b>LYMPHATIC SYSTEM</b>	60	30	30	0	15	10	13	21	1	0
HODGKIN'S DISEASE	6	1	5	0	1	2	1	2	0	0
NON-HODGKIN'S	54	29	25	0	14	8	12	19	1	0
<b>UNKNOWN PRIMARY</b>	19	10	9	0	0	0	0	0	0	19
<b>OTHER/ILL-DEFINED</b>	5	4	1	0	1	0	1	1	0	2

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

Number of cases excluded: 0

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION FOR 2013 OSBORN**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
<b>ALL SITES</b>	<b>613</b>	<b>272</b>	<b>341</b>	<b>33</b>	<b>161</b>	<b>95</b>	<b>59</b>	<b>129</b>	<b>38</b>	<b>98</b>
<b>ORAL CAVITY</b>	19	18	1	0	4	3	3	6	3	0
LIP	0	0	0	0	0	0	0	0	0	0
TONGUE	9	8	1	0	1	1	3	2	2	0
OROPHARYNX	0	0	0	0	0	0	0	0	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	10	10	0	0	3	2	0	4	1	0
<b>DIGESTIVE SYSTEM</b>	100	62	38	3	20	24	15	30	8	0
ESOPHAGUS	6	4	2	0	2	1	0	1	2	0
STOMACH	5	2	3	0	2	0	2	1	0	0
COLON	34	21	13	2	4	11	7	10	0	0
RECTUM	19	13	6	0	3	3	4	5	4	0
ANUS/ANAL CANAL	3	0	3	0	1	1	1	0	0	0
LIVER	12	9	3	0	6	0	1	5	0	0
PANCREAS	15	10	5	0	2	8	0	5	0	0
OTHER	6	3	3	1	0	0	0	3	2	0
<b>RESPIRATORY SYSTEM</b>	110	50	60	1	27	14	17	49	1	1
NASAL/SINUS	1	1	0	0	1	0	0	0	0	0
LARYNX	6	6	0	1	2	0	1	2	0	0
LUNG/BRONCHUS	101	42	59	0	23	14	16	46	1	1
OTHER	2	1	1	0	1	0	0	1	0	0
<b>BLOOD &amp; BONE MARROW</b>	33	15	18	0	0	0	1	1	0	31
LEUKEMIA	20	9	11	0	0	0	1	1	0	18
MULTIPLE MYELOMA	6	2	4	0	0	0	0	0	0	6
OTHER	7	4	3	0	0	0	0	0	0	7
<b>BONE</b>	2	2	0	0	2	0	0	0	0	0
<b>CONNECT/SOFT TISSUE</b>	13	11	2	0	1	1	7	1	2	1

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

<b>SKIN</b>	66	34	32	7	26	14	3	5	7	4
MELANOMA	61	32	29	7	25	12	3	5	7	2
OTHER	5	2	3	0	1	2	0	0	0	2
<b>BREAST</b>	102	2	100	17	49	22	7	5	2	0
<b>FEMALE GENITAL</b>	11	0	11	0	2	0	1	0	7	1
CERVIX UTERI	1	0	1	0	0	0	0	0	1	0
CORPUS UTERI	5	0	5	0	1	0	0	0	4	0
OVARY	3	0	3	0	1	0	1	0	1	0
VULVA	1	0	1	0	0	0	0	0	1	0
OTHER	1	0	1	0	0	0	0	0	0	1
<b>MALE GENITAL</b>	5	5	0	0	0	0	0	5	0	0
PROSTATE	5	5	0	0	0	0	0	5	0	0
TESTIS	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0
<b>URINARY SYSTEM</b>	21	19	2	5	5	2	1	8	0	0
BLADDER	9	8	1	4	1	1	1	2	0	0
KIDNEY/RENAL	10	10	0	0	4	1	0	5	0	0
OTHER	2	1	1	1	0	0	0	1	0	0
<b>BRAIN &amp; CNS</b>	32	13	19	0	0	0	0	0	0	32
BRAIN (BENIGN)	1	1	0	0	0	0	0	0	0	1
BRAIN (MALIGNANT)	15	7	8	0	0	0	0	0	0	15
OTHER	16	5	11	0	0	0	0	0	0	16
<b>ENDOCRINE</b>	23	6	17	0	10	0	1	3	7	2
THYROID	21	5	16	0	10	0	1	3	7	0
OTHER	2	1	1	0	0	0	0	0	0	2
<b>LYMPHATIC SYSTEM</b>	52	25	27	0	15	13	2	16	1	5
HODGKIN'S DISEASE	6	3	3	0	1	4	0	1	0	0
NON-HODGKIN'S	46	22	24	0	14	9	2	15	1	5
<b>UNKNOWN PRIMARY</b>	17	8	9	0	0	0	0	0	0	17
<b>OTHER/ILL-DEFINED</b>	7	2	5	0	0	2	1	0	0	4

Number of cases excluded: 1

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION FOR 2013 TPK**

PRIMARY SITE	TOTAL	GENDER		AJCC STAGE						
		Male	Female	0	I	II	III	IV	UNK	N/A
<b>ALL SITES</b>	<b>354</b>	<b>144</b>	<b>210</b>	<b>15</b>	<b>122</b>	<b>50</b>	<b>59</b>	<b>52</b>	<b>30</b>	<b>26</b>
<b>ORAL CAVITY</b>	4	3	1	0	1	0	0	3	0	0
LIP	0	0	0	0	0	0	0	0	0	0
TONGUE	1	1	0	0	1	0	0	0	0	0
OROPHARYNX	1	0	1	0	0	0	0	1	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0
OTHER	2	2	0	0	0	0	0	2	0	0
<b>DIGESTIVE SYSTEM</b>	54	28	26	0	11	18	10	12	2	1
ESOPHAGUS	1	1	0	0	0	1	0	0	0	0
STOMACH	3	1	2	0	1	1	0	1	0	0
COLON	23	12	11	0	5	9	5	3	0	1
RECTUM	14	7	7	0	4	3	4	1	2	0
ANUS/ANAL CANAL	0	0	0	0	0	0	0	0	0	0
LIVER	2	1	1	0	1	0	0	1	0	0
PANCREAS	6	4	2	0	0	2	0	4	0	0
OTHER	5	2	3	0	0	2	1	2	0	0
<b>RESPIRATORY SYSTEM</b>	31	16	15	0	8	2	9	10	2	0
NASAL/SINUS	0	0	0	0	0	0	0	0	0	0
LARYNX	1	1	0	0	0	0	0	1	0	0
LUNG/BRONCHUS	30	15	15	0	8	2	9	9	2	0
OTHER	0	0	0	0	0	0	0	0	0	0
<b>BLOOD &amp; BONE MARROW</b>	13	10	3	0	0	0	1	1	0	11
LEUKEMIA	9	6	3	0	0	0	1	1	0	7
MULTIPLE MYELOMA	1	1	0	0	0	0	0	0	0	1
OTHER	3	3	0	0	0	0	0	0	0	3
<b>BONE</b>	0	0	0	0	0	0	0	0	0	0
<b>CONNECT/SOFT TISSUE</b>	4	1	3	0	2	0	2	0	0	0
<b>SKIN</b>	5	1	4	0	1	1	2	0	0	1
MELANOMA	4	1	3	0	0	1	2	0	0	1
OTHER	1	0	1	0	1	0	0	0	0	0
<b>BREAST</b>	10	0	10	1	3	2	1	1	2	0
<b>FEMALE GENITAL</b>	111	0	111	1	54	5	21	13	16	1
CERVIX UTERI	17	0	17	0	9	1	4	1	2	0
CORPUS UTERI	64	0	64	0	40	0	7	6	11	0
OVARY	19	0	19	0	3	0	9	4	3	0
VULVA	11	0	11	1	2	4	1	2	0	1

Scottsdale Healthcare Shea 2014 Cancer Program Annual Report

OTHER	0	0	0	0	0	0	0	0	0	0
<b>MALE GENITAL</b>	43	43	0	0	22	15	4	1	1	0
PROSTATE	41	41	0	0	22	14	4	1	0	0
TESTIS	1	1	0	0	0	1	0	0	0	0
OTHER	1	1	0	0	0	0	0	0	1	0
<b>URINARY SYSTEM</b>	35	27	8	13	14	3	0	3	2	0
BLADDER	19	17	2	10	5	2	0	2	0	0
KIDNEY/RENAL	12	9	3	0	8	1	0	1	2	0
OTHER	4	1	3	3	1	0	0	0	0	0
<b>BRAIN &amp; CNS</b>	0	0	0	0	0	0	0	0	0	0
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0
<b>ENDOCRINE</b>	12	2	10	0	5	2	0	2	3	0
THYROID	12	2	10	0	5	2	0	2	3	0
OTHER	0	0	0	0	0	0	0	0	0	0
<b>LYMPHATIC SYSTEM</b>	11	6	5	0	1	2	3	5	0	0
HODGKIN'S DISEASE	0	0	0	0	0	0	0	0	0	0
NON-HODGKIN'S	11	6	5	0	1	2	3	5	0	0
<b>UNKNOWN PRIMARY</b>	10	5	5	0	0	0	0	0	0	10
<b>OTHER/ILL-DEFINED</b>	11	2	9	0	0	0	6	1	2	2

Number of cases excluded: 0

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases